CYP2C9 等位基因查询表
等位基因 |
蛋白质 |
核苷酸变化 |
影响 |
酶活性变化 |
参考文献 |
||
体内 |
体外 |
||||||
CYP2C9*1A |
None |
None |
|
|
|
||
CYP2C9*1B Predicted haplotype |
CYP2C9.1 |
|
-2665_-2664delTG, |
|
|
|
|
CYP2C9*1C Predicted haplotype |
CYP2C9.1 |
|
|
|
|
||
CYP2C9*1D Predicted haplotype |
CYP2C9.1 |
|
-2665_-2664delTG |
|
|
|
|
CYP2C9*2A Predicted haplotype |
CYP2C9.2 |
|
Decr |
Rettie et al., 1994 |
|||
CYP2C9*2B Predicted haplotype |
CYP2C9.2 |
-2665_-2664delTG, |
|
Decr |
|||
CYP2C9*2C Predicted haplotype |
CYP2C9.2 |
-1096A>G; -620G>T; |
|
Decr |
|||
CYP2C9*3A Predicted haplotype |
CYP2C9.3 |
-1911T>C; -1885C>G; |
Decr |
Decr |
Sullivan-Klose et al., 1996 |
||
CYP2C9*3B Predicted haplotype |
CYP2C9.3 |
Decr |
Decr |
||||
CYP2C9*4 |
CYP2C9.4 |
|
|
||||
CYP2C9*5 |
CYP2C9.5 |
Decr? |
Decr |
Dickmann et al., 2001 |
|||
CYP2C9*6 |
|
None |
|
||||
CYP2C9*7 |
CYP2C9.7 |
|
|
||||
CYP2C9*8 |
CYP2C9.8 |
Decr |
Incr/Decr |
||||
CYP2C9*9 |
CYP2C9.9 |
|
|
||||
CYP2C9*10 |
CYP2C9.10 |
|
|
||||
CYP2C9*11A Predicted haplotype |
CYP2C9.11 |
Decr |
Decr |
Higashi et al., 2002 |
|||
CYP2C9*11B Predicted haplotype |
CYP2C9.11 |
|
Decr |
||||
CYP2C9*12 |
CYP2C9.12 |
|
Decr |
||||
CYP2C9*13 |
CYP2C9.13 |
Decr |
Decr |
||||
CYP2C9*14 |
CYP2C9.14 |
|
Decr |
||||
CYP2C9*15 |
|
None |
|||||
CYP2C9*16 |
CYP2C9.16 |
|
Decr |
||||
CYP2C9*17 |
CYP2C9.17 |
1144C>T |
42683C>T |
P382S |
|
|
|
CYP2C9*18 |
CYP2C9.18 |
-1911T>C; -1885C>G; |
|
Decr |
|||
CYP2C9*19 |
CYP2C9.19 |
1362G>C |
-1188T>C; 50235G>C |
Q454H |
|
|
|
CYP2C9*20 |
CYP2C9.20 |
208G>C |
-1188T>C; 3215G>C |
G70R |
|
|
|
CYP2C9*21 |
CYP2C9.21 |
|
|
||||
CYP2C9*22 |
CYP2C9.22 |
121A>G |
121A>G |
N41D |
|
|
|
CYP2C9*23 |
CYP2C9.23 |
226G>A |
3233G>A |
V76M |
|
|
|
CYP2C9*24 |
CYP2C9.24 |
1060G>A Existence of the CYP2C9*2 polymorphism 430C>T on the same allele cannot be excluded |
42599G>A |
E354K |
|
|
|
CYP2C9*25 |
353_362delAGAAATGGAA |
3531_3540delAGAAATGGAA |
118Frameshift |
|
None |
||
CYP2C9*26 |
CYP2C9.26 |
389C>G |
1565C>T; -1188T>C; 3567C>G; 3856G>A; 8763C>T; 9032G>C; 10311A>G; 33349A>G; 50056A>T |
T130R |
|
Decr |
|
CYP2C9*27 |
CYP2C9.27 |
449G>T |
-3089G>A; -2665_-2664delTG; |
R150L |
|
|
|
CYP2C9*28 |
CYP2C9.28 |
641A>T |
9256A>T |
Q214L |
|
Decr |
|
CYP2C9*29 |
CYP2C9.29 |
251T>C; 3411T>C; 33437C>A; 33658A>G; 50056A>T |
|
|
|||
CYP2C9*30 |
CYP2C9.30 |
1429G>A |
50302G>A |
A477T |
|
Decr |
|
CYP2C9*31 |
CYP2C9.31 |
|
|
||||
CYP2C9*32 |
CYP2C9.32 |
1468G>T |
50341G>T |
V490F |
|
|
|
CYP2C9*33 |
CYP2C9.33 |
|
Decr |
||||
CYP2C9*34 |
CYP2C9.34 |
1004G>A |
42543G>A |
R335Q |
|
|
|
CYP2C9*35 |
CYP2C9.35 |
374G>T; 430C>T |
3552G>T; 3608C>T |
R125L; R144C |
|
None |
CYP2C9*36 |
CYP2C9.36 |
|
|
||||
CYP2C9*37 |
CYP2C9.37 |
146A>G |
146A>G |
D49G |
|
|
|
CYP2C9*38 |
CYP2C9.38 |
287G>C |
3294G>C |
G96A |
|
|
|
CYP2C9*39 |
CYP2C9.39 |
293G>T |
3300G>T |
G98V |
|
|
|
CYP2C9*40 |
CYP2C9.40 |
329T>C |
3336T>C |
F110S |
|
|
|
CYP2C9*41 |
CYP2C9.41 |
356A>G |
3534A>G |
K119R |
|
|
|
CYP2C9*42 |
CYP2C9.42 |
|
|
||||
CYP2C9*43 |
CYP2C9.43 |
370C>T |
3548C>T |
R124W |
|
|
|
CYP2C9*44 |
CYP2C9.44 |
|
|
||||
CYP2C9*45 |
CYP2C9.45 |
|
|
||||
CYP2C9*46 |
CYP2C9.46 |
445G>A |
3623G>A |
A149T |
|
|
|
CYP2C9*47 |
CYP2C9.47 |
488C>T |
9103C>T |
P163L |
|
|
|
CYP2C9*48 |
CYP2C9.48 |
620T>C |
9235T>C |
I207T |
|
|
|
CYP2C9*49 |
CYP2C9.49 |
664A>G |
10447A>G |
I222V |
|
|
|
CYP2C9*50 |
CYP2C9.50 |
679C>T |
10462C>T |
P227S |
|
|
|
CYP2C9*51 |
CYP2C9.51 |
850A>G |
33452A>G |
I284V |
|
|
|
CYP2C9*52 |
CYP2C9.52 |
896C>G |
33498C>G |
T299R |
|
|
|
CYP2C9*53 |
CYP2C9.53 |
949C>T |
33551C>T |
P317S |
|
|
|
CYP2C9*54 |
CYP2C9.54 |
1029C>A |
42568C>A |
S343R |
|
|
|
CYP2C9*55 |
CYP2C9.55 |
1081C>A |
42620C>A |
L361I |
|
|
|
CYP2C9*56 |
CYP2C9.56 |
1159A>G |
47360A>G |
I387V |
|
|
|
CYP2C9*57 |
CYP2C9.57 |
610A>C |
9225A>C |
N204H |
|
|
|
CYP2C9*58 |
CYP2C9.58 |
1009C>A |
42548C>A |
P337T |
|
|
|
CYP2C9*59 |
CYP2C9.59 |
1300A>T |
50173A>T |
I434F |
Decr |
Found in an outlier |
|
CYP2C9*60 |
CYP2C9.60 |
Decr |
Found in an outlier |
Additional SNPs, where the haplotype has not yet been determined |
|||||||
|
|
|
96C>G; 251T>C; 2191T>A; 2340G>A; 2638G>T; 2737T>C; 3162G>C; 3235G>A; 3898C>T; 3924T>C; 4033A>G; 4157C>T; 4309A>G; 4628T>A; 4670G>T; 9032G>C; 9069G>A; 10682T>C; 10787G>A; 10814G>T; 33658A>G; 42469T>C; 42726C>T; 47545A>T; 47593T>C; 50053G>A; 50066G>A; 50081G>C; 50434C>T; 50454C>G; 50566A>G; 50658A>G; 50742T>A; 52104C>A; 52175T>C; 52236C>T; 52319G>C; 53194insTGACAT; 53403C>T; 53498delT; 53538G>C; 53557T>C |
|
|
|
|
|
|
|
49C>A |
L17I |
|
|
|
|
|
|
|
|
|||
|
|
|
-8897C>A; -8553C>A; |
|
|
|
|
|
|
|
|
|
|||
|
|
8C>A |
|
S3Y |
|
|
|
|
|
1078G>A |
|
D360N |
|
|
|
|
|
1253A>C |
|
N418T |
|
|
- 【佳学基因检测】非小细胞肺癌抗药后基因检测所带来的新方案...
- 【佳学基因靶向药物基因检测】 BRAF V600E 突变的非小细胞肺癌腹膜癌患者对加曲美替尼的有希望的反应...
- 【佳学基因靶向药物基因检测】与突变无关的 RNA 干扰工程替代品可挽救与 Tmc1 相关的听力损失...
- 【佳学基因检测】基因病基因缺陷疾病的基因治疗...
- 【佳学基因检测】达拉非尼疗法和BRAF基因型基因检测...
- 【佳学基因检测】右侧单冠状缝早闭症基因筛查测试...
- 【佳学基因检测】如何使用威诺利克(Venclexta)治疗白血病患者?...
- 【佳学基因检测】食道癌高水平治疗使用的曲妥珠单抗(Herceptin)病理检测指标...
- 【佳学基因检测】白血病降低痛苦用药使用维甲酸(Vesanoid)分子诊断结果...
- 【佳学基因检测】乳腺癌曲妥珠单抗(Kadcyla)靶向药物基因检测...
- 【佳学基因检测】得了胃癌如何采用尼沃鲁单抗(Opdivo)进行靶向治疗?...
- 【佳学基因检测】头颈癌增加治疗效果时选用的帕姆单抗(Keytruda)基因检测依据...
- 【佳学基因检测】使用帕姆单抗(Keytruda治疗子宫内膜癌之前要做什么基因检测?...
- 【佳学基因检测】使用阿韦珠单抗(Bavencio)治疗内分泌和神经内分泌肿瘤,会减少病人痛苦吗?...
- 【佳学基因检测】肺癌药物处方治疗曲美替尼(Mekinist)基因检测信息...
- 【佳学基因检测】食道癌尼沃鲁单抗(Opdivo)正确医学基因检测...
- 【佳学基因检测】肺癌如何使用特普替尼(Tepmetko)会产生靶向药效果...
- 【佳学基因检测】胃肠道间质瘤舒尼替尼(Sutent)靶向治疗基因检测...
- 【佳学基因检测】肝癌和胆管癌选择非替尼(Inrebic)基因检测指标...
- 【佳学基因检测】乳腺癌正确治疗使用的玛格曲希单抗(Margenza)的前提条件...
- 【佳学基因检测】肺癌什么时候选择甲磺酸奥希替尼(Tagrisso)达到正确医学水平?...
- 【佳学基因检测】使用普拉替尼(Gavreto)治疗肺癌,肿瘤会不会减小?...
- 【佳学基因检测】身体任何部位的实体瘤使用靶向药物治疗曲美替尼(Mekinist)所需NGS结果...
- 【佳学基因检测】什么样的结直肠癌患者需要使用齐夫-阿飞单抗(Zaltrap)?...
- 【佳学基因检测】使用沃利替尼(Zolinza)治疗淋巴瘤之前要做什么基因检测?...
- 【佳学基因检测】淋巴瘤患者如何知道是否需要使用赞布鲁汀(Brukinsa)?...
- 【佳学基因检测】膀胱癌降低痛苦用药使用沙西他胺戈维替坎(Trodelvy)分子诊断结果...
- 【佳学基因检测】乳腺癌增加治疗效果时选用的沙西他胺戈维替坎(Trodelvy)基因检测依据...
- 【佳学基因检测】淋巴瘤增加治疗效果时选用的塞林昔(Xpovio)基因测试要求依据...
- 【佳学基因检测】如何采用基因检测增加塞林昔(Xpovio)对多发性骨髓瘤的治疗效果?...
- 来了,就说两句!
-
- 最新评论 进入详细评论页>>